Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company's product candidates within the Core Program include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:QURE
- CUSIP: N/A
- Web: www.uniqure.com
Capitalization:- Market Cap: $196.81 million
- Outstanding Shares: 25,560,000
Average Prices:- 50 Day Moving Avg: $7.77
- 200 Day Moving Avg: $6.23
- 52 Week Range: $4.72 - $9.15
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.92
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $24.62 million
- Price / Sales: 7.99
- Book Value: $1.07 per share
- Price / Book: 7.20
Profitability:- EBIDTA: ($59,260,000.00)
- Net Margins: -203.99%
- Return on Equity: -135.97%
- Return on Assets: -40.45%
Debt:- Debt-to-Equity Ratio: 0.59%
- Current Ratio: 4.82%
- Quick Ratio: 4.82%
Misc:- Average Volume: 140,502 shs.
- Beta: 0.42
- Short Ratio: 5.43
Frequently Asked Questions for uniQure N.V. (NASDAQ:QURE)
What is uniQure N.V.'s stock symbol?
uniQure N.V. trades on the NASDAQ under the ticker symbol "QURE."
How were uniQure N.V.'s earnings last quarter?
uniQure N.V. (NASDAQ:QURE) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.05. The company had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.92 million. uniQure N.V. had a negative net margin of 203.99% and a negative return on equity of 135.97%. View uniQure N.V.'s Earnings History.
When will uniQure N.V. make its next earnings announcement?
Where is uniQure N.V.'s stock going? Where will uniQure N.V.'s stock price be in 2017?
7 brokers have issued twelve-month target prices for uniQure N.V.'s shares. Their forecasts range from $8.00 to $27.00. On average, they expect uniQure N.V.'s share price to reach $16.00 in the next twelve months. View Analyst Ratings for uniQure N.V..
What are analysts saying about uniQure N.V. stock?
Here are some recent quotes from research analysts about uniQure N.V. stock:
- 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (8/24/2017)
- 2. Cowen and Company analysts commented, "QURE reported 1Q17 financials and presented multiple updates at ASGCT recently." (5/24/2017)
Who are some of uniQure N.V.'s key competitors?
Some companies that are related to uniQure N.V. include Mersana Therapeutics (MRSN), BioCryst Pharmaceuticals (BCRX), GlycoMimetics (GLYC), Ra Pharmctl (RARX), BioSpecifics Technologies Corp (BSTC), Geron Corporation (GERN), Edge Therapeutics (EDGE), Corbus Pharmaceuticals Holdings (CRBP), BioTime (BTX), Rigel Pharmaceuticals (RIGL), CymaBay Therapeutics (CBAY), Akebia Therapeutics (AKBA), Merus N.V. (MRUS), Oxford BioMedica plc (OXB), Bellicum Pharmaceuticals (BLCM), Minerva Neurosciences (NERV), Circassia Pharmaceuticals PLC (CIR) and Tocagen (TOCA).
Who owns uniQure N.V. stock?
uniQure N.V.'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.13%), Spark Investment Management LLC (1.02%), Tekla Capital Management LLC (0.95%), DAFNA Capital Management LLC (0.80%), P.A.W. Capital Corp (0.49%) and Macquarie Group Ltd. (0.28%). View Institutional Ownership Trends for uniQure N.V..
Who sold uniQure N.V. stock? Who is selling uniQure N.V. stock?
Who bought uniQure N.V. stock? Who is buying uniQure N.V. stock?
How do I buy uniQure N.V. stock?
Shares of uniQure N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is uniQure N.V.'s stock price today?
One share of uniQure N.V. stock can currently be purchased for approximately $7.70.
MarketBeat Community Rating for uniQure N.V. (NASDAQ QURE)MarketBeat's community ratings are surveys of what our community members think about uniQure N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for uniQure N.V. (NASDAQ:QURE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.71) |
| Consensus Price Target: | $16.00 (107.79% upside) |
Analysts' Ratings History for uniQure N.V. (NASDAQ:QURE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/23/2017 | Chardan Capital | Set Price Target | Buy | $13.00 | High |  |
| 6/30/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $17.00 | Low | |
| 5/24/2017 | Cowen and Company | Reiterated Rating | Buy | | Medium | |
| 4/12/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $8.00 | Low | |
| 12/2/2016 | Leerink Swann | Reiterated Rating | Outperform | | N/A | |
| 12/6/2016 | WallachBeth Capital | Lower Price Target | Buy | $27.00 -> $15.00 | N/A | |
| 11/15/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | | N/A | |
| 8/4/2016 | HC Wainwright | Initiated Coverage | Buy | $21.00 | N/A | |
| 1/8/2016 | Janney Montgomery Scott | Reiterated Rating | Buy | | N/A | |
| 1/8/2016 | Roth Capital | Reiterated Rating | Buy | $37.00 | N/A | |
(Data available from 8/24/2015 forward)
Earnings History for uniQure N.V. (NASDAQ:QURE)Earnings History by Quarter for uniQure N.V. (NASDAQ QURE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/28/2017 | | | | | | | | |
| 8/8/2017 | 6/30/2017 | ($0.78) | ($0.83) | $2.92 million | $4.94 million | View | N/A | |
| 5/9/2017 | 3/31/2017 | ($0.64) | ($0.80) | $4.20 million | $3.32 million | View | N/A | |
| 5/31/2016 | Q1 | ($0.82) | ($0.93) | $2.94 million | $4.30 million | View | N/A | |
| 4/4/2016 | Q415 | ($0.60) | ($0.58) | $2.78 million | $6.78 million | View | N/A | |
| 11/30/2015 | Q315 | ($0.64) | ($1.14) | $7.76 million | $3.50 million | View | Listen | |
| 8/27/2015 | Q215 | ($0.56) | ($0.98) | $31.18 million | $1.79 million | View | N/A | |
| 6/11/2015 | Q1 | ($0.82) | ($0.69) | $9.50 million | $1.17 million | View | N/A | |
| 4/6/2015 | | ($0.62) | ($0.77) | $1.38 million | $1.61 million | View | N/A | |
| 12/1/2014 | | ($0.53) | ($0.61) | $2.00 million | $1.30 million | View | N/A | |
| 9/2/2014 | Q214 | ($0.55) | ($1.35) | $1.40 million | $1.37 million | View | N/A | |
| 6/6/2014 | | ($0.45) | ($0.52) | $0.84 million | $1.59 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for uniQure N.V. (NASDAQ:QURE)2017 EPS Consensus Estimate: ($3.04)
2018 EPS Consensus Estimate: ($2.90)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.71) | ($0.71) | ($0.71) |
| Q2 2017 | 2 | ($0.81) | ($0.71) | ($0.76) |
| Q3 2017 | 2 | ($0.85) | ($0.84) | ($0.85) |
| Q4 2017 | 2 | ($0.86) | ($0.58) | ($0.72) |
| Q1 2018 | 1 | ($0.81) | ($0.81) | ($0.81) |
| Q2 2018 | 1 | ($0.80) | ($0.80) | ($0.80) |
| Q3 2018 | 1 | ($0.81) | ($0.81) | ($0.81) |
| Q4 2018 | 1 | ($0.48) | ($0.48) | ($0.48) |
(Data provided by Zacks Investment Research)
Dividend History for uniQure N.V. (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for uniQure N.V. (NASDAQ:QURE)
Latest Headlines for uniQure N.V. (NASDAQ:QURE)
| Source: |
|
uniQure N.V. (QURE) Chart for Thursday, August, 24, 2017
